Explore the Global Lung Cancer Diagnostics Market— analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

Lung Cancer Diagnostics Market

Key Insight

Lung Cancer Diagnostics Market was valued at USD 13.30 Billion in 2025. Sales are expected to reach USD 14.30 Billion in 2026 and USD 29.47 Billion by 2036. Non-small cell lung cancer is poised to lead by Type with 68.7% share in 2026 and EGFR Mutation test is estimated to command by Test with 40.8% share in 2026.

March 23, 2026

Anurag Sharma

250 Pages

Cite this Report

Lung Cancer Diagnostics Market

https://www.futuremarketinsights.com/reports/lung-cancer-diagnostics-market

License

Buy Now

Summary ToC Companies

Key Players

Abbott
Agilent Technologies
Bio-Rad
F. Hoffmann-La Roche Ag
Illumina
Myriad Genetics
NeoGenomics Laboratories
Qiagen
Thermo Fisher Scientific Inc.

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Lung Cancer Diagnostics Market

Key Players

Similar Industry Reports